drugset / Trial / NCT03204786
Intranasal Vasopressin Treatment in Children With Autism
Phase 2/3
Completed
157 enrolled
Stanford University
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this clinical trial is to investigate the effectiveness of vasopressin nasal spray for treating symptoms associated with autism. Vasopressin is a hormone that is produced naturally within the body and has been implicated in regulating social behaviors. It has been proposed that administration of the hormone may also help improve social functioning in individuals with autism.
Timeline
- Start
- 2018-02-20
- Primary completion
- 2024-03-18
- Completion
- 2024-03-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vasopressin | Peptide | 16 iu | Intranasal |